ReviewFrontiers in pharmacology2025
Inhibition of mesenchymal drift as a strategy for rejuvenation.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal drift (MD), the progressive acquisition of mesenchymal traits by epithelial and endothelial cells, has emerged as a unifying mechanism of aging. Transcriptomic analyses across human tissues reveal that mesenchymal programs intensify with age and predict morbidity and mortality. By eroding lineage identity and promoting fibrosis, MD disrupts organ integrity in the lung, liver, kidney, heart, and brain. Mechanistically, it converges with epigenetic erosion, chronic inflammation, and extracellular matrix stiffening to establish self-reinforcing loops of dysfunction. Interventions that restore cellular identity can suppress MD: transient reprogramming resets epigenetic age and reduces fibrotic signatures without loss of identity, while chemical cocktails achieve similar rejuvenation effects with enhanced translational potential. Together, these findings establish MD as a tentative hallmark of aging and suggest that its inhibition could represent a strategy for cellular and tissue rejuvenation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.